This manuscript summarizes current primary resistance of Helicobacter pylori to antibiotics in Brussels in 2021. Resistance rates were estimated at 18% for clarithromycin, 24% for levofloxacin, 52% for metronidazole, and 0% for amoxicillin and tetracycline. When compared to 2016, resistance rates remain stable, except an increase of 30% for metronidazole.

All the scientific societies recommend tailoring Helicobacter pylori eradication therapy to strain susceptibility or at least to the rate of the local primary resistance to antimicrobials, particularly in adult patients [1,2]. This paper aims to update the local primary antimicrobial resistance of H. pylori obtained in the Laboratoire Hospitalier Universitaire de Bruxelles – Universitair Laboratorium Brussel (LHUB-ULB) serving a huge number of endoscopy clinics in Belgium and particularly in

The manuscript has not been published or submitted elsewhere.

All authors have seen and approved the manuscript.

V.Y. Miendje Deyi performed the study conception, data collection, analysis and writing of the manuscript. R. Ntounda, H. Louis, N.L. Kahegeshe, M. Nkuize, A. Burette, K. Kotilea, M. Van Gossum, M. Delhaye and P. Bontems contributed to the collection of clinical information's, design and writing of the manuscript.

None to declare.

There are more references available in the full text version of this article.

© 2022 Elsevier Inc. All rights reserved.